Optiscan Imaging has reached an 84-case milestone in its live digital pathology study with Australian Clinical Labs, testing the InForm platform across a broad range of tissue types and disease settings. The data may support future regulatory submissions and commercial discussions, but the announcement does not disclose diagnostic accuracy metrics or regulatory approval.
- 84 cases imaged at ACL’s Western Australian pathology laboratory
- Study spans multiple tissue types, cancers and clinical use cases
- InForm images are being compared with conventional H&E slides
- Data intended to support workflow refinement, training and future submissions
- No quantified accuracy results, approval or commercial launch date disclosed
ACL Study Reaches 84 Cases
Optiscan Imaging Ltd (ASX:OIL) has passed a significant clinical-validation milestone, imaging 84 cases with its InForm™ digital pathology device inside Australian Clinical Labs’ flagship anatomical pathology laboratory in Western Australia. The study is testing whether real-time, slide-free cellular imaging can operate in a high-throughput pathology environment rather than a controlled demonstration setting.
The cases cover tissue from a wide range of organ systems, including breast, gastrointestinal, urinary, reproductive, respiratory, kidney, liver, prostate, eye and skin samples. The study also includes normal, benign, inflammatory, premalignant and malignant pathology, giving Optiscan a broad set of real-world conditions against which to assess the platform.
Real-Time Images Tested Against Standard Slides
InForm captures cellular-level digital images as specimens move through ACL’s centralised laboratory. Pathologists can assess those images against conventional haematoxylin and eosin-stained glass slides, allowing the company to examine image quality, workflow integration and performance across repeated cases.
Optiscan says the first 84 cases included all soft-tissue cancer types evident in the study and that InForm generated high-resolution images recapitulating the detail of standard H&E slides. That is a company-reported observation, not a disclosed diagnostic-performance result: the announcement provides no sensitivity, specificity, concordance analysis or other quantified accuracy measure.
Data Aimed at Regulatory and Commercial Milestones
ACL’s network gives Optiscan access to more than 40 accredited laboratories, over 60 RCPA-accredited pathologists and 1,273 collection centres. For Optiscan, the value of the collaboration lies not only in the case count but in the opportunity to refine imaging protocols, gather feedback from pathologists and laboratory scientists, and build training materials and validation datasets.
The company says those outputs are expected to support future regulatory submissions in Australia and the United States, as well as later commercial discussions. The study has established a reference site in a leading pathology organisation, but the filing does not announce a regulatory submission, clearance, binding commercial agreement or launch timetable. The next material test is whether the growing dataset becomes formal clinical evidence that regulators and pathology providers can rely on.
Bottom Line?
The 84-case milestone strengthens InForm’s real-world evidence base, but regulatory progress and commercial adoption still depend on quantified clinical performance and formal approvals.
Questions in the middle?
- Will Optiscan disclose quantified diagnostic performance as the ACL dataset expands?
- When will the company convert the study evidence into formal Australian or US regulatory submissions?
- Can the InForm workflow demonstrate enough practical value to secure commercial adoption beyond the ACL reference site?